**Background**
Bacterial infections remain a significant global health challenge, particularly those caused by Gram-negative and Gram-positive pathogens. Infections of the respiratory tract, urinary tract, and ear, nose, and throat often require potent antimicrobial agents to prevent systemic complications. Furthermore, syphilis, caused by the spirochete Treponema pallidum, necessitates specific therapeutic interventions to eliminate the pathogen and prevent long-term neurological or cardiovascular damage. Cephalosporins, a class of $\beta$-lactam antibiotics, are essential tools in treating these conditions due to their ability to interfere with bacterial cell wall synthesis. In this context, we will introduce a potent cephalosporin antibiotic – Cefetamet.
**Definition**
Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of cefetamet pivoxil. It targets bacterial penicillin-binding proteins (PBPs), with an $\text{IC}_{50}$ for PBP3 in Escherichia coli W3110 of 2.5 $\mu\text{g/mL}$.
**In Vitro and In Vivo Studies**
According to the Cefetamet description, this compound exhibits broad-spectrum activity against various pathogens. Cefetamet in vitro studies demonstrate high activity against most members of the Enterobacteriaceae, Haemophilus influenzae, Neisseria spp., and Streptococcus pneumoniae, with $\text{MIC}_{90}$ values $\le 2\ \mu\text{g/mL}$. It also shows high activity against Vibrio spp. and streptococci other than enterococci. However, it exhibits poor affinity for the PBPs of Staphylococcus aureus, with $\text{IC}_{50}$ values for PBP 1 to 4 ranging from 52 to $>100\ \mu\text{g/mL}$. Notably, Cefetamet (0.05-0.1 $\mu\text{g/mL}$; 24 h) is capable of killing and lysing Treponema pallidum in vitro.
Regarding Cefetamet In Vivo activity, the compound has been evaluated in animal models of syphilis. Administration of Cefetamet (1-30 mg/kg; i.m.; once) successfully cures experimental syphilis in rabbits, achieving the best therapeutic effect when administered before the onset of clinical manifestations. For researchers seeking detailed Cefetamet technical information, these results highlight its potential in treating spirochetal infections. In conclusion, Cefetamet is a potent $\beta$-lactam antibiotic with significant activity against a wide range of Gram-negative and certain Gram-positive bacteria.
Keywords
Cefetamet, 65052-63-3, Ro 15-8074, Deacetoxycefotaxime, Antibiotic, Bacterial, Penicillin-binding protein (PBP), Drug Metabolite, cephalosporin, antibiotic, respiratory tract infections, Inhibitor, inhibitor, inhibit
References
[1] Bryson HM, et al. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1993;45(4):589-621.
[2] Wang W, et al. Pharmacokinetics and pharmacodynamics of oral and intravenous cefetamet in dog. Eur J Drug Metab Pharmacokinet. 2015 Dec;40(4):401-7.
[3] Wise R, et al. In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother. 1986 Jun;29(6):1067-72.
[4] Angehrn P, et al. In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil. Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):536-43.
[5] Fitzgerald TJ. Effects of cefetamet (Ro 15-8074) on Treponema pallidum and experimental syphilis. Antimicrob Agents Chemother. 1992 Mar;36(3):598-602.